OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Naqash on Combining Abequolixron Plus Docetaxel in Recurrent NSCLC

November 26th 2024

Abdul Rafeh Naqash, MD, discusses the potential role for abequolixron plus docetaxel in recurrent advanced non–small cell lung cancer.

Dr Kumthekar on CSF Tumor Detection in Breast Cancer or NSCLC with Leptomeningeal Disease

November 25th 2024

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.

Dr Schiff on PFS and OS Data With Temozolomide Plus Radiation in Grade II Glioma

November 25th 2024

David Schiff, MD, discusses PFS and OS data for radiation with or without temozolomide in patients with grade II glioma.

Dr Gershon on Deep Responses With Mirdametinib in NF1-PN

November 24th 2024

Timothy Gershon, MD, PhD, discusses an analysis of patients with NF1-PN who achieved deep responses with mirdametinib in the phase 2b ReNeu study.

Dr Hansford on HRQOL Outcomes With Tovorafenib in Pediatric BRAF-Altered Low-Grade Glioma

November 23rd 2024

Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.

Dr Harding on the FDA Approval of Zanidatamab for HER2+ Biliary Tract Cancer

November 23rd 2024

James J. Harding, MD, discusses the significance of the FDA approval of zanidatamab for pretreated, unresectable or metastatic HER2+ biliary tract cancer.

Dr Elder on the Initial Safety Profile of IGV-001 in Newly Diagnosed Glioblastoma

November 23rd 2024

J. Bradley Elder, MD, discusses blinded early-safety data from a phase 2b trial of IGV-001 in patients with newly diagnosed glioblastoma.

Dr Lukas on Survival Outcomes With Eflornithine in IDH-Mutant Anaplastic Astrocytoma

November 22nd 2024

Rimas V. Lukas, MD, discusses the efficacy of eflornithine plus lomustine in recurrent IDH-mutant anaplastic astrocytoma per 2021 WHO diagnostic criteria.

Dr Singer on Toxicities Associated With First-Line IO/TKI Regimens in RCC

November 22nd 2024

Adam E. Singer, MD, PhD, discusses the safety profiles of immuno-oncology/TKI regimens in first-line renal cell carcinoma.

Dr Reidy-Lagunes on the Evolving NET Treatment Paradigm

November 22nd 2024

Diane Reidy-Lagunes, MD, discusses key trials that have expanded the treatment paradigm for patients with neuroendocrine tumors.

Dr Pant on the Importance of Targeted Therapy and Mutation Testing in Pancreatic Cancer

November 22nd 2024

Shubham Pant, MD, MBBS, discusses next-generation sequencing in pancreatic cancer, highlighting the importance of targeting RAS mutations when applicable.

Dr Kalinsky on the Implications of DESTINY-Breast06 for T-DXd Use in HER2-Ultralow Breast Cancer

November 22nd 2024

Kevin Kalinsky, MD, MS, discusses the phase 3 DESTINY-Breast06 trial evaluating trastuzumab deruxtecan in HER2-expressing breast cancer.

Dr Ecker on the Role of CAPETEM in the Treatment of Pancreatic NETs

November 22nd 2024

Dr Janjigian on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

November 22nd 2024

Yelena Y. Janjigian, MD, discusses the significance of the FDA approval of zolbetuximab plus chemotherapy for HER2–, CLDN18.2+ gastric/GEJ adenocarcinoma.

Dr Hochster on the Role of Cooperative Trials in Academic and Community Health Care Settings

November 21st 2024

Howard S. Hochster, MD, FACP, discusses the role of cooperative group clinical trials in bridging the gap between academic and community cancer centers.

Dr Strickler on the Role of Biomarker Testing in Pancreatic Cancer

November 21st 2024

John H. Strickler, MD, discusses the role of biomarker testing in metastatic pancreatic cancer.

Dr Smaglo on the Evolution of RAS-Targeted Therapies for Pancreatic Cancer

November 21st 2024

Brandon G. Smaglo, MD, FACP, discusses the ongoing research with RAS-targeted therapies for pancreatic cancer.

Dr Pobel on the Prognostic Value of Phenotypic and Genomic Characterization in De Novo mCSPC

November 20th 2024

Cedric Pobel, MD, discusses the potential prognostic value of phenotypic and genomic characterization of de novo mCSPC from the phase 3 PEACE-1 trial.

Dr O’Regan on Sequencing Considerations in Advanced HR+ Breast Cancer

November 20th 2024

Ruth O'Regan, MD, discusses considerations for sequencing strategies in advanced hormone receptor–positive breast cancer.

Dr Grunwald on Monitoring Risk Factors for Disease Progression in PV

November 20th 2024

Michael R. Grunwald, MD, discusses the importance of monitoring risk factors associated with disease progression in patients with polycythemia vera.